THE TGA has provisionally approved Minjuvi (tafasitamab) for use in Australia.
The approval is "in combination with lenalidomide followed by Minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant," shared its manufacturer Specialised Therapeutics.
Learn more HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 28 Jun 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Jun 23
Warning: Undefined variable $o_shortcode_atts in /home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line 1263
Warning: Undefined variable $output in /home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line 1266
